Venus Remedies Limited — Important, 25-02-2025: Updates

Venus Remedies Ltd has secured exclusive licensing rights from Infex Therapeutics to develop and commercialize MET-X in India. MET-X is a novel metallo-beta-lactamase (MBL) inhibitor designed to tackle drug-resistant Gram-negative infections, an urgent medical challenge in India, where meropenem resistance is noted to be as high as 62-87% for critical pathogens. The initial development phase will focus on clinical trials, commencing with a Phase I study involving healthy volunteers to evaluate MET-X in combination with meropenem.

This strategic partnership positions Venus Remedies to enhance its leadership in critical care and antibiotic R&D while aligning with the significant market opportunity created by the lack of existing MBL inhibitors in India. The agreement also allows both companies the option to expand collaborations for additional combinations involving MET-X, thereby reinforcing their commitment to addressing the rising threat of antimicrobial resistance. Overall, this development highlights a positive outlook for Venus Remedies, bolstering its capabilities in the critical care pharmaceutical market.